| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
'Ictal epileptic headache': recent concepts for new classifications criteria.
|
Cephalalgia
|
2012
|
3.19
|
|
2
|
Lifting the burden: the first 7 years.
|
J Headache Pain
|
2010
|
2.55
|
|
3
|
New policies to consolidate the journal's hold on its latest position.
|
J Headache Pain
|
2009
|
2.33
|
|
4
|
A tier-upon-tier march towards the impact factor.
|
J Headache Pain
|
2008
|
2.09
|
|
5
|
While climbing the hill, you think it's possible.
|
J Headache Pain
|
2009
|
1.97
|
|
6
|
Headache disorders are third cause of disability worldwide.
|
J Headache Pain
|
2015
|
1.93
|
|
7
|
The Journal of Headache and Pain keeps gaining consensus.
|
J Headache Pain
|
2010
|
1.70
|
|
8
|
Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk.
|
J Headache Pain
|
2009
|
1.60
|
|
9
|
The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action.
|
J Headache Pain
|
2011
|
1.52
|
|
10
|
Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.
|
Intern Emerg Med
|
2015
|
1.52
|
|
11
|
Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?
|
Intern Emerg Med
|
2010
|
1.49
|
|
12
|
Time to act on headache disorders.
|
J Headache Pain
|
2011
|
1.47
|
|
13
|
The definitive position of headache among the major public health challenges. An end to the slippery slope of disregard.
|
J Headache Pain
|
2007
|
1.40
|
|
14
|
Neuromodulation of chronic headaches: position statement from the European Headache Federation.
|
J Headache Pain
|
2013
|
1.39
|
|
15
|
Chronic migraine plus medication overuse headache: two entities or not?
|
J Headache Pain
|
2011
|
1.39
|
|
16
|
Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
|
J Headache Pain
|
2006
|
1.38
|
|
17
|
Psychiatric comorbidity and suicide risk in patients with chronic migraine.
|
Neuropsychiatr Dis Treat
|
2010
|
1.37
|
|
18
|
Headache and emergency medicine: sharing a language for a common project.
|
Intern Emerg Med
|
2008
|
1.36
|
|
19
|
Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation.
|
J Headache Pain
|
2014
|
1.31
|
|
20
|
Psychometric properties of the stagnation scale in medication overuse headache patients.
|
J Headache Pain
|
2015
|
1.29
|
|
21
|
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.
|
J Headache Pain
|
2011
|
1.22
|
|
22
|
Framing education on headache disorders into the Global Burden of Disease Study 2010. The European Headache Federation stands ready.
|
J Headache Pain
|
2013
|
1.19
|
|
23
|
Chronicling the June conundrum.
|
J Headache Pain
|
2011
|
1.18
|
|
24
|
The Global Burden of Disease survey 2010, Lifting The Burden and thinking outside-the-box on headache disorders.
|
J Headache Pain
|
2013
|
1.17
|
|
25
|
Emerging treatment for chronic migraine and refractory chronic migraine.
|
Expert Opin Emerg Drugs
|
2012
|
1.10
|
|
26
|
A six year retrospective review of occipital nerve stimulation practice--controversies and challenges of an emerging technique for treating refractory headache syndromes.
|
J Headache Pain
|
2013
|
1.09
|
|
27
|
Framing comorbidities and co-occurrences in a migraine with aura patient.
|
Intern Emerg Med
|
2014
|
1.07
|
|
28
|
Prevalence and burden of primary headache in Akaki textile mill workers, Ethiopia.
|
J Headache Pain
|
2008
|
1.05
|
|
29
|
Headache medicine: academic teaching in Europe. The Sapienza University Master's Degree.
|
Headache
|
2007
|
1.05
|
|
30
|
Tumor necrosis factor gene polymorphism in migraine.
|
Headache
|
2002
|
1.04
|
|
31
|
A tasty cultural event.
|
J Headache Pain
|
2012
|
1.04
|
|
32
|
New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?
|
J Headache Pain
|
2013
|
1.02
|
|
33
|
Academic specialist education in headache medicine. Next move for the headache community.
|
J Headache Pain
|
2005
|
1.02
|
|
34
|
Chronic migraine: comorbidities, risk factors, and rehabilitation.
|
Intern Emerg Med
|
2010
|
1.02
|
|
35
|
Ictal epileptic headache: an old story with courses and appeals.
|
J Headache Pain
|
2012
|
1.02
|
|
36
|
Refractory headache: one term does not cover all--a statement of the European Headache Federation.
|
J Headache Pain
|
2014
|
0.95
|
|
37
|
Overattachment and perceived disability in chronic migraineurs.
|
Clin Neurol Neurosurg
|
2012
|
0.94
|
|
38
|
Improving care through health economics analyses: cost of illness and headache.
|
J Headache Pain
|
2008
|
0.93
|
|
39
|
Future drugs for migraine.
|
Intern Emerg Med
|
2009
|
0.93
|
|
40
|
Pharmacokinetic evaluation of almotriptan for the treatment of migraines.
|
Expert Opin Drug Metab Toxicol
|
2013
|
0.92
|
|
41
|
Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.
|
J Headache Pain
|
2010
|
0.89
|
|
42
|
Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache.
|
J Headache Pain
|
2008
|
0.89
|
|
43
|
Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.
|
Patient Relat Outcome Meas
|
2010
|
0.88
|
|
44
|
White matter hyperintensities and self-reported depression in a sample of patients with chronic headache.
|
J Headache Pain
|
2012
|
0.88
|
|
45
|
The validation of the Italian Perceived Disability Scale (IPDS) in chronic daily headache sufferers.
|
J Headache Pain
|
2008
|
0.87
|
|
46
|
Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations.
|
J Headache Pain
|
2013
|
0.87
|
|
47
|
Pharmacokinetic evaluation of frovatriptan.
|
Expert Opin Drug Metab Toxicol
|
2011
|
0.86
|
|
48
|
Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine.
|
J Headache Pain
|
2010
|
0.86
|
|
49
|
Treatment of perimenstrual migraine with triptans: an update.
|
Curr Pain Headache Rep
|
2012
|
0.86
|
|
50
|
Update on Medication-Overuse Headache and Its Treatment.
|
Curr Treat Options Neurol
|
2015
|
0.84
|
|
51
|
Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice.
|
Expert Opin Pharmacother
|
2012
|
0.84
|
|
52
|
Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.
|
J Headache Pain
|
2012
|
0.84
|
|
53
|
Genetics of migraine and pharmacogenomics: some considerations.
|
J Headache Pain
|
2007
|
0.83
|
|
54
|
Sodium channel antagonists for the treatment of migraine.
|
Expert Opin Pharmacother
|
2014
|
0.83
|
|
55
|
Salivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine.
|
J Headache Pain
|
2006
|
0.82
|
|
56
|
Treatment of menstrual migraine: utility of control of related mood disturbances.
|
Expert Rev Neurother
|
2014
|
0.82
|
|
57
|
Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy.
|
Expert Opin Drug Metab Toxicol
|
2010
|
0.82
|
|
58
|
Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines.
|
Expert Opin Drug Metab Toxicol
|
2012
|
0.82
|
|
59
|
Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.
|
Expert Opin Pharmacother
|
2013
|
0.81
|
|
60
|
Pharmacogenomics in migraine: catching biomarkers for a predictable disease control [corrected].
|
Expert Rev Neurother
|
2009
|
0.81
|
|
61
|
CGRP receptor antagonists: an expanding drug class for acute migraine?
|
Expert Opin Investig Drugs
|
2012
|
0.81
|
|
62
|
Headache and mood disorders.
|
J Headache Pain
|
2005
|
0.80
|
|
63
|
Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches.
|
Expert Opin Drug Metab Toxicol
|
2014
|
0.80
|
|
64
|
Deciphering the task of N-acetyl aspartate in migraine.
|
Expert Rev Neurother
|
2012
|
0.79
|
|
65
|
Emerging drugs for migraine treatment.
|
Expert Opin Emerg Drugs
|
2014
|
0.78
|
|
66
|
Pharmacogenetic insights into migraine treatment in children.
|
Pharmacogenomics
|
2014
|
0.78
|
|
67
|
Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migraine.
|
J Headache Pain
|
2005
|
0.77
|
|
68
|
Migraine with aura, bipolar depression, ACM aneurysm. A case report.
|
J Headache Pain
|
2005
|
0.77
|
|
69
|
Dispute settlement understanding on the use of Botox in chronic migraine.
|
J Headache Pain
|
2011
|
0.76
|
|
70
|
Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class.
|
Expert Rev Neurother
|
2008
|
0.76
|
|
71
|
The omics in migraine.
|
J Headache Pain
|
2013
|
0.76
|
|
72
|
Aspirin and tension-type headache.
|
J Headache Pain
|
2007
|
0.76
|
|
73
|
Efficacy and tolerability of almotriptan in menstrual migraine: a comment.
|
Expert Opin Pharmacother
|
2011
|
0.76
|
|
74
|
The therapeutic potential of novel anti-migraine acute therapies.
|
Expert Opin Investig Drugs
|
2014
|
0.76
|
|
75
|
Neuroendocrine derangement in chronic migraine.
|
Headache
|
2006
|
0.75
|
|
76
|
Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population.
|
Expert Rev Neurother
|
2015
|
0.75
|